Microalgae technology startup Xiaozao completed round B financing of hundreds of millions of yuan. This round of financing will continue to be used for product R&D and breeding scale expansion in the field of microalgae, further enhance the monopoly position of microalgae technology in algal EPA, and further expand to the market of health products, drugs, and chronic disease management in the field of cardiovascular.
The core of Xiaozao is microalgae, the gospel of life on earth. It is the main creator of oxygen in the process of earth evolution and one of the oldest living organisms in the world. Its derivatives are widely used in various fields, including medicine, food processing, health nutrition, and animal feed. At the same time, microalgae also have a strong carbon neutralization ability. Cultivating a ton of microalgae can consume at least 1.8 tons of carbon dioxide. In the global environment of carbon emission reduction, the microalgae breeding industry has unlimited possibilities.
At present, the core product of Xiaozao is EPA (eicosapentaenoic acid), which is a kind of polyunsaturated fatty acid. It is one of the essential nutrients that cannot be produced by the human body independently. It has the characteristics of anti-inflammatory, anti-oxidation, and softening blood vessels. It has certain effects in the treatment of cardiovascular diseases, depression, weight loss, and exercise. Because of its important effect in the treatment of cardiovascular diseases, it is known as a "vascular scavenger".
EPA microalgae oil plays an important role in the field of medicine and health and can help many patients at risk of disease. In addition, the production mode of EPA microalgae oil is low-carbon, environmental-friendly, recyclable and sustainable, which is the new economic development mode most needed in this era.